The Probiotics in Pediatric Asthma Management (PROPAM) Study in the Primary Care Setting: A Randomized, Controlled, Double-Blind Trial with Ligilactobacillus salivarius LS01 (DSM 22775) and Bifidobacterium breve B632 (DSM 24706)

Author:

Drago Lorenzo1ORCID,Cioffi Luigi2ORCID,Giuliano Maria2,Pane Marco3ORCID,Amoruso Angela3,Schiavetti Irene4ORCID,Reid Gregor5ORCID,Ciprandi Giorgio6ORCID,PROPAM Study Group 2

Affiliation:

1. Department of Biomedical Sciences for Health, University of Milan, Milan, Italy

2. Pediatric Primary Care ASL Napoli 2, Naples, Italy

3. Research and Development, Probiotical Research, Novara, Italy

4. Health Science Department, University of Genoa, Genoa, Italy

5. Departments of Microbiology, Immunology and Surgery, Western University, London, ON, Canada

6. Allergy Clinic, Casa di Cura Villa Montallegro, Genoa, Italy

Abstract

Background. Type-2 inflammation commonly marks asthma in childhood. Also, gut and lung dysbiosis is detectable in patients with asthma. Strain-related probiotic supplementation may restore a physiological immune response, dampen airway inflammation, and repair dysbiosis. Therefore, the probiotics in pediatric asthma management (PROPAM) study is aimed at demonstrating that Ligilactobacillus salivarius LS01 (DSM 22775) and Bifidobacterium breve B632 (DSM 24706) mixture could reduce asthma exacerbations in children, followed in a primary care setting. Methods. The study was randomized, placebo-controlled, and double-blind. It involved 11 Italian primary care pediatricians. The probiotic mixture (containing Ligilactobacillus salivarius LS01 1 × 10 9 live cells and Bifidobacterium breve B632 1 × 10 9 live cells) or placebo was taken twice daily (1 sachet in the morning and 1 in the evening) for eight weeks and subsequently once daily for a further eight weeks. Outcomes included number, severity, and duration of asthma exacerbations, intensity of maintenance and as need treatments, and safety. Results. The per-protocol population included 422 children (mean age seven years, 240 males and 182 females). The probiotic mixture significantly reduced the number of asthmatic exacerbations ( OR = 3.17 ). In addition, the number of children with two exacerbations was less than a third in the active group ( OR = 3.65 ). Conclusions. This PROPAM study demonstrated that probiotic strains Ligilactobacillus salivarius LS01 (DSM 22775) and Bifidobacterium breve B632 (DSM 24706) were safe and significantly reduced by more than a third the frequency of asthma exacerbations. At present, the first-line treatment of asthma is still drug-based, but specific strains of probiotics may be auxiliary remedies.

Publisher

Hindawi Limited

Subject

Immunology,General Medicine,Immunology and Allergy

Reference28 articles.

1. Respiratory viruses and asthma;P. A. B. Wark;Seminars in Respiratory and Critical Care Medicine,2018

2. Prevention of asthma: targets for intervention;M. C. Maciag;Chest,2020

3. Atopic march: collegium Internationale Allergologicum Update 2020;M. Aw;International Archives of Allergy and Immunology,2020

4. A biodiversity hypothesis;T. Haahtela;Allergy,2019

5. Dysbiosis of the gut and lung microbiome has a role in asthma

Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3